FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385458045> ?p ?o ?g. }

• W4385458045 abstract "<div>Abstract<p>Mutations in <i>KRAS</i> are found in more than 50% of tumors from patients with metastatic colorectal cancer (mCRC). However, direct targeting of most <i>KRAS</i> mutations is difficult; even the recently developed KRAS^G12C inhibitors failed to show significant benefit in patients with mCRC. Single agents targeting mitogen-activated protein kinase kinase (MEK), a downstream mediator of RAS, have also been ineffective in colorectal cancer. To identify drugs that can enhance the efficacy of MEK inhibitors, we performed unbiased high-throughput screening using colorectal cancer spheroids. We used trametinib as the anchor drug and examined combinations of trametinib with the NCI-approved Oncology Library version 5. The initial screen, and following focused validation screens, identified vincristine as being strongly synergistic with trametinib. <i>In vitro</i>, the combination strongly inhibited cell growth, reduced clonogenic survival, and enhanced apoptosis compared with monotherapies in multiple KRAS-mutant colorectal cancer cell lines. Furthermore, this combination significantly inhibited tumor growth, reduced cell proliferation, and increased apoptosis in multiple KRAS-mutant patient-derived xenograft mouse models<i>. In vivo</i> studies using drug doses that reflect clinically achievable doses demonstrated that the combination was well tolerated by mice. We further determined that the mechanism underlying the synergistic effect of the combination was due to enhanced intracellular accumulation of vincristine associated with MEK inhibition. The combination also significantly decreased p-mTOR levels <i>in vitro</i>, indicating that it inhibits both RAS-RAF-MEK and PI3K-AKT-mTOR survival pathways. Our data thus provide strong evidence that the combination of trametinib and vincristine represents a novel therapeutic option to be studied in clinical trials for patients with KRAS-mutant mCRC.</p>Significance:<p>Our unbiased preclinical studies have identified vincristine as an effective combination partner for the MEK inhibitor trametinib and provide a novel therapeutic option to be studied in patients with KRAS-mutant colorectal cancer.</p></div>" @default.
• W4385458045 created "2023-08-02" @default.
• W4385458045 creator A5006348751 @default.
• W4385458045 creator A5006530291 @default.
• W4385458045 creator A5025375045 @default.
• W4385458045 creator A5028702533 @default.
• W4385458045 creator A5030825527 @default.
• W4385458045 creator A5035961942 @default.
• W4385458045 creator A5042341684 @default.
• W4385458045 creator A5055380623 @default.
• W4385458045 creator A5060823826 @default.
• W4385458045 creator A5061781457 @default.
• W4385458045 creator A5063114221 @default.
• W4385458045 creator A5070102283 @default.
• W4385458045 creator A5079659253 @default.
• W4385458045 date "2023-08-01" @default.
• W4385458045 modified "2023-09-27" @default.
• W4385458045 title "Data from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer" @default.
• W4385458045 doi "https://doi.org/10.1158/1535-7163.c.6769266" @default.
• W4385458045 hasPublicationYear "2023" @default.
• W4385458045 type Work @default.
• W4385458045 citedByCount "0" @default.
• W4385458045 crossrefType "posted-content" @default.
• W4385458045 hasAuthorship W4385458045A5006348751 @default.
• W4385458045 hasAuthorship W4385458045A5006530291 @default.
• W4385458045 hasAuthorship W4385458045A5025375045 @default.
• W4385458045 hasAuthorship W4385458045A5028702533 @default.
• W4385458045 hasAuthorship W4385458045A5030825527 @default.
• W4385458045 hasAuthorship W4385458045A5035961942 @default.
• W4385458045 hasAuthorship W4385458045A5042341684 @default.
• W4385458045 hasAuthorship W4385458045A5055380623 @default.
• W4385458045 hasAuthorship W4385458045A5060823826 @default.
• W4385458045 hasAuthorship W4385458045A5061781457 @default.
• W4385458045 hasAuthorship W4385458045A5063114221 @default.
• W4385458045 hasAuthorship W4385458045A5070102283 @default.
• W4385458045 hasAuthorship W4385458045A5079659253 @default.
• W4385458045 hasConcept C117262875 @default.
• W4385458045 hasConcept C121608353 @default.
• W4385458045 hasConcept C126322002 @default.
• W4385458045 hasConcept C184235292 @default.
• W4385458045 hasConcept C185592680 @default.
• W4385458045 hasConcept C190283241 @default.
• W4385458045 hasConcept C2778472372 @default.
• W4385458045 hasConcept C2781187634 @default.
• W4385458045 hasConcept C2781249067 @default.
• W4385458045 hasConcept C502942594 @default.
• W4385458045 hasConcept C526805850 @default.
• W4385458045 hasConcept C55493867 @default.
• W4385458045 hasConcept C57074206 @default.
• W4385458045 hasConcept C62112901 @default.
• W4385458045 hasConcept C71924100 @default.
• W4385458045 hasConcept C86803240 @default.
• W4385458045 hasConcept C95444343 @default.
• W4385458045 hasConcept C98274493 @default.
• W4385458045 hasConceptScore W4385458045C117262875 @default.
• W4385458045 hasConceptScore W4385458045C121608353 @default.
• W4385458045 hasConceptScore W4385458045C126322002 @default.
• W4385458045 hasConceptScore W4385458045C184235292 @default.
• W4385458045 hasConceptScore W4385458045C185592680 @default.
• W4385458045 hasConceptScore W4385458045C190283241 @default.
• W4385458045 hasConceptScore W4385458045C2778472372 @default.
• W4385458045 hasConceptScore W4385458045C2781187634 @default.
• W4385458045 hasConceptScore W4385458045C2781249067 @default.
• W4385458045 hasConceptScore W4385458045C502942594 @default.
• W4385458045 hasConceptScore W4385458045C526805850 @default.
• W4385458045 hasConceptScore W4385458045C55493867 @default.
• W4385458045 hasConceptScore W4385458045C57074206 @default.
• W4385458045 hasConceptScore W4385458045C62112901 @default.
• W4385458045 hasConceptScore W4385458045C71924100 @default.
• W4385458045 hasConceptScore W4385458045C86803240 @default.
• W4385458045 hasConceptScore W4385458045C95444343 @default.
• W4385458045 hasConceptScore W4385458045C98274493 @default.
• W4385458045 hasLocation W43854580451 @default.
• W4385458045 hasOpenAccess W4385458045 @default.
• W4385458045 hasPrimaryLocation W43854580451 @default.
• W4385458045 hasRelatedWork W2060440543 @default.
• W4385458045 hasRelatedWork W2162044478 @default.
• W4385458045 hasRelatedWork W2164992866 @default.
• W4385458045 hasRelatedWork W2602578690 @default.
• W4385458045 hasRelatedWork W2741304831 @default.
• W4385458045 hasRelatedWork W4225272646 @default.
• W4385458045 hasRelatedWork W4296809296 @default.
• W4385458045 hasRelatedWork W4309889913 @default.
• W4385458045 hasRelatedWork W4318067865 @default.
• W4385458045 hasRelatedWork W4385922719 @default.
• W4385458045 isParatext "false" @default.
• W4385458045 isRetracted "false" @default.
• W4385458045 workType "article" @default.